PMID- 38541124 OWN - NLM STAT- MEDLINE DCOM- 20240329 LR - 20240330 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 60 IP - 3 DP - 2024 Feb 26 TI - Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review. LID - 10.3390/medicina60030398 [doi] LID - 398 AB - Background and Objectives: More than 430,000 new cases of renal cell carcinoma (RCC) were reported in 2020. Clear cell RCC, which occurs in 80% of cases, is often associated with mutations in the VHL gene, leading to dysregulation of hypoxia-induced transcription factors pathways and carcinogenesis. The purpose of this study is to examine the adverse events (AEs) of cabozantinib treatment and the relationship between individual patient factors and the frequency of their occurrence in detail. Materials and Methods: Seventy-one patients with metastatic RCC were treated with second or further lines of cabozantinib at the Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology. Comprehensive data, including demographics, clinicopathological factors, and AEs, were collected from January 2017 to June 2021. This study evaluated the impact of various patient-related factors on the rate of adverse events and treatment tolerance using a Cox proportional hazards model. Results: Cabozantinib-induced AEs were significantly associated with body mass index (BMI), body surface area (BSA), IMDC prognostic score, and treatment line. Notably, patients receiving cabozantinib post-tyrosine kinase inhibitors reported fewer AEs. Dose reduction was unrelated to adverse event frequency, but patients requiring dose reduction were characterized with lower body mass and BSA but not BMI. Conclusions: The factors described make it possible to predict the incidence of AEs, which allows for faster detection and easier management, especially in the high-risk group. AEs should be reported in detail in real-world studies, as their occurrence has a significant impact on prognosis. FAU - Domanski, Piotr AU - Domanski P AUID- ORCID: 0009-0003-2205-4093 AD - Department of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Pietak, Mateusz AU - Pietak M AUID- ORCID: 0000-0001-6451-1238 AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Staneta, Szymon AU - Staneta S AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Fortuniak, Weronika AU - Fortuniak W AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Kruczyk, Barbara AU - Kruczyk B AUID- ORCID: 0009-0001-5782-7151 AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Kobiernik, Adam AU - Kobiernik A AUID- ORCID: 0009-0003-4879-6837 AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Bakula, Piotr AU - Bakula P AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Mydlak, Anna AU - Mydlak A AD - Department of Head and Neck Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Demkow, Tomasz AU - Demkow T AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Sikora-Kupis, Bozena AU - Sikora-Kupis B AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. FAU - Dumnicka, Paulina AU - Dumnicka P AUID- ORCID: 0000-0003-3667-857X AD - Chair of Biochemistry, Jagiellonian University Medical College, 31-034 Krakow, Poland. FAU - Kucharz, Jakub AU - Kucharz J AUID- ORCID: 0000-0001-5388-8910 AD - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20240226 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 1C39JW444G (cabozantinib) RN - 0 (Anilides) RN - 0 (Pyridines) SB - IM MH - Humans MH - *Carcinoma, Renal Cell/drug therapy MH - Retrospective Studies MH - *Kidney Neoplasms/drug therapy MH - Prognosis MH - *Anilides MH - *Pyridines PMC - PMC10972126 OTO - NOTNLM OT - Tyrosine Kinase Inhibitors (TKIs) OT - adverse events (AEs) OT - cabozantinib OT - clear cell renal cell carcinoma (ccRCC) OT - prognostic factors COIS- Honoraria: Angelini, Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, IPSEN, Janssen, Merck MSD, Novartis, Pfizer, Research Funding: Novartis. All unrelated to the present paper. EDAT- 2024/03/28 06:46 MHDA- 2024/03/29 06:45 PMCR- 2024/02/26 CRDT- 2024/03/28 01:11 PHST- 2024/01/22 00:00 [received] PHST- 2024/02/18 00:00 [revised] PHST- 2024/02/20 00:00 [accepted] PHST- 2024/03/29 06:45 [medline] PHST- 2024/03/28 06:46 [pubmed] PHST- 2024/03/28 01:11 [entrez] PHST- 2024/02/26 00:00 [pmc-release] AID - medicina60030398 [pii] AID - medicina-60-00398 [pii] AID - 10.3390/medicina60030398 [doi] PST - epublish SO - Medicina (Kaunas). 2024 Feb 26;60(3):398. doi: 10.3390/medicina60030398.